Skip to content
10-K

Annual Report

X4 Pharmaceuticals, Inc XFOR

0001501697-26-000018

← back to feed
Filed
Mar 17, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 12, 2026 90.92M sh
Shares Diluted FY 2025 · Dec 31, 2025 42.29M sh
Shares Diluted restated FY 2025 · Dec 31, 2024 6.7M sh
Shares Diluted restated FY 2025 · Dec 31, 2023 5.93M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$85.62M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$130.9M
Operating Cash Flow FY 2025 · Dec 31, 2023 −$96.51M
Cash And Equivalents FY 2025 · Dec 31, 2025 $217.05M
Cash And Equivalents FY 2025 · Dec 31, 2024 $55.7M
Stockholders Equity FY 2025 · Dec 31, 2025 $186.29M
Stockholders Equity FY 2025 · Dec 31, 2024 $22.15M
Stockholders Equity FY 2025 · Dec 31, 2023 $51.1M
Stockholders Equity FY 2025 · Dec 31, 2022 $74.05M
Current Liabilities FY 2025 · Dec 31, 2025 $25.76M
Current Liabilities FY 2025 · Dec 31, 2024 $32.88M
Total Liabilities FY 2025 · Dec 31, 2025 $104.17M
Total Liabilities FY 2025 · Dec 31, 2024 $124.3M
Current Assets FY 2025 · Dec 31, 2025 $261.58M
Current Assets FY 2025 · Dec 31, 2024 $112.18M
Total Assets FY 2025 · Dec 31, 2025 $290.46M
Total Assets FY 2025 · Dec 31, 2024 $146.45M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.87
Eps Diluted restated FY 2025 · Dec 31, 2024 −$5.59
Eps Diluted restated FY 2025 · Dec 31, 2023 −$17.07
Eps Basic FY 2025 · Dec 31, 2025 −$1.87
Eps Basic restated FY 2025 · Dec 31, 2024 −$5.59
Eps Basic restated FY 2025 · Dec 31, 2023 −$17.07
Sga Expense FY 2025 · Dec 31, 2025 $43.52M
Sga Expense FY 2025 · Dec 31, 2024 $61.52M
Sga Expense FY 2025 · Dec 31, 2023 $35.51M
Rd Expense FY 2025 · Dec 31, 2025 $72.72M
Rd Expense FY 2025 · Dec 31, 2024 $81.64M
Rd Expense FY 2025 · Dec 31, 2023 $72.02M
Net Income FY 2025 · Dec 31, 2025 −$79.2M
Net Income FY 2025 · Dec 31, 2024 −$37.45M
Net Income FY 2025 · Dec 31, 2023 −$101.17M
Operating Income FY 2025 · Dec 31, 2025 −$86.88M
Operating Income FY 2025 · Dec 31, 2024 −$36.4M
Operating Income FY 2025 · Dec 31, 2023 −$107.52M
Cost Of Revenue FY 2025 · Dec 31, 2025 $5.76M
Cost Of Revenue FY 2025 · Dec 31, 2024 $797K
Cost Of Revenue FY 2025 · Dec 31, 2023 $0
Revenue FY 2025 · Dec 31, 2025 $35.11M
Revenue FY 2025 · Dec 31, 2024 $2.56M
Revenue FY 2025 · Dec 31, 2023 $0